Plain-English translation of NCT04853251 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a tiny implant called the Port Delivery System (PDS) that is surgically placed in your eye to continuously deliver ranibizumab, a medication that helps slow vision loss from age-related macular degeneration. Instead of getting repeated eye injections every month, the device releases the medication steadily and is refilled every 24 weeks. Researchers want to make sure the implant doesn't harm the front part of your eye (the cornea) while delivering this treatment.
Many patients with age-related macular degeneration need frequent injections into their eye to prevent vision loss, which can be uncomfortable and inconvenient. This trial exists to see if an implanted device can deliver the medication continuously without those repeated injections, while staying safe for your eye.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will have a surgical procedure to implant the small delivery device in your study eye. After surgery, you will return for regular follow-up visits where doctors will examine your eye, take photographs, and perform imaging tests to check how well the device is working and whether your cornea remains healthy. The implant will be refilled with fresh medication every 24 weeks (about every 6 months) during a brief office procedure. The trial involves about 188 patients at multiple medical centers.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States